Table 35, Summary of included studies. Comparison 34. Augmenting with bupropion versus placebo - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
Gulrez 2012 RCT India	N=60 Mean age (years): 41.2 Gender (% female): 52 Ethnicity (% BME): NR Baseline severity: HAMD 17.67 (more severe)	Bupropion sustained release 300mg/day (target dose, titrated upwards from 150mg in first week) + SSRI	Placebo + SSRI	Inadequate response (HAMD score ≥16) after 4 weeks of SSRI treatment	Treatment length (weeks): 4 Outcomes: Remission

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

India

N=60

Mean age (years): 41.2

Gender (% female): 52

Ethnicity (% BME): NR

Baseline severity: HAMD 17.67 (more severe)

Bupropion sustained release 300mg/day (target dose, titrated upwards from 150mg in first week) + SSRI

Placebo + SSRI

Inadequate response (HAMD score ≥16) after 4 weeks of SSRI treatment

Treatment length (weeks): 4

Outcomes:

: BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial; SSRI: selective serotonin reuptake inhibitor

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.